Endometrial cancer hormone-related

Taking the contraceptive hormones provides health benefits not related to contraception, such as regulating the menstrual cycle and decreased blood loss, and incidence of iron deficiency anemia, and dysmenorrhea Health benefits related to the inhibition of ovulation include a decrease in ovarian cysts and ectopic pregnancies. hi addition, there is a decrease in fibrocyctic breast disease, acute pelvic inflammatory disease endometrial cancer, ovarian cancer, maintenance of bone density, and symptoms related to endometriosis in women taking contraceptive hormones. Newer combination contraceptives such as norgestimate and ethinyl estradiol... 

According to results from clinical trials, the agonistic effects of tamoxifen detected in animals were also observed in the human uterus as it produces a trophic effect and an increase in the incidence of endometrial pathology, which is related to endometrial thickening (> 4 mm). Its use seems to be associated with an increase in endometrial cancer, which is related to the length of treatment and the accumulated dose of tamoxifen. Nevertheless, these tumors do not seem to be more aggressive or to have a worse prognosis than those found in women who do not follow this treatment or who receive hormone therapy. 

Hormone Receptors. Certain types of cancer, mainly breast cancer, endometrial cancer, and prostate cancer, show a growth dependency on sexual hormones such as estradiol and testosterone [26]. As those cells overexpress hormone receptors, down-regulation of the hormone concentration is a powerful tool in the fight against those cancer types. Among the chemotherapeutics approved for treatment is tamoxifen [27, 28]. In recent years, also related complexes, that is, the ferrocifenes [29] were developed for that purpose. For detailed information on this class of molecules, please see Chapter 42. 

---